AI Article Synopsis
- DC-CIK immunotherapy, which combines dendritic cells and cytokine-induced killer cells, shows promise as a potential treatment for non-small-cell lung cancer (NSCLC) based on extensive research.
- A meta-analysis of 6 randomized controlled trials with 505 patients revealed that DC-CIK significantly improves progression-free survival (PFS), overall survival (OS), and disease control rates (DCR) compared to standard treatments, although it did not enhance objective response rates (ORR).
- The safety profile of DC-CIK immunotherapy is comparable to that of control therapies, with no additional serious side effects, highlighting the need for further research to establish its routine clinical application.
Article Abstract
Dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) immunotherapy has been widely studied and might be a new therapeutic strategy for non-small-cell lung cancer (NSCLC). We aimed to comprehensively and quantitatively evaluate the efficacy and safety of DC-CIK immunotherapy in NSCLC. Pubmed, Embase, Cochrane Library, and Web of Science were searched for randomized controlled trials comparing DC-CIK immunotherapy with control therapies in NSCLC. A total of 505 patients from 6 trials were enrolled. Compared with control therapies, DC-CIK immunotherapy significantly improved progression-free survival (PFS) [hazard ratio (HR): 0.528, 95% confidence interval (CI): 0.390-0.715, P<0.001], overall survival (OS) (HR: 0.619, 95% CI: 0.487-0.786, P<0.001), and disease control rates (DCR) [relative risk (RR): 1.250, 95% CI: 1.058-1.477, P=0.009], but objective response rates (ORR) (RR: 1.190, 95% CI: 0.561-2.526, P=0.650) was not improved for DC-CIK immunotherapy. The risks of all-grade anemia, leukopenia, dermatosis, diarrhea, nausea, acratia, and chest distress in patients receiving DC-CIK immunotherapy were comparable to those receiving control therapies. This meta-analysis demonstrates DC-CIK immunotherapy has superiority in PFS, OS, and DCR for NSCLC patients, and no more serious adverse events appeared. Further studies to provide solid evidence for the routine clinical use of DC-CIK immunotherapy are urgently needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2015.05.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma.
Sci Rep
January 2025
Department of Stereotactic and Functional Neurosurgery, University Hospital of Bonn, 53127, Bonn, Germany.
Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with glioblastoma (GBM) has opened a new avenue for adoptive cellular immunotherapies in CNS malignancies. Prompt from these findings, herein, we investigated whether dendritic cells (DC) in combination with cytokine-induced killer cells (DC-CIK) could also provide an alternative and more effective way to improve the efficacy of GBM treatment.
View Article and Find Full Text PDFCombined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials.
J Transl Med
December 2024
Department of Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of DC-CIK immunotherapy by assessing overall survival, progression-free survival, overall response rate, disease control rate, and adverse events in relevant randomized controlled trials. The results of this analysis will contribute to optimizing treatment strategies and improving cancer immunotherapy outcomes.
View Article and Find Full Text PDFEffects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer.
World J Gastrointest Surg
October 2024
Department of Oncology, General Hospital of Northern Theater Command, Shenyang 110016, Liaoning Province, China.
Background: The outcome of surgical treatment for colorectal cancer (CRC) remains unsatisfactory and warrants further exploration and optimization.
Aim: To clarify the impact of chemotherapy plus cellular immunotherapy [dendritic cell-cytokine-induced killer (DC-CIK) cell immunotherapy] on patients after CRC surgery and to explore the mediating variables.
Methods: A total cohort of 121 patients who underwent CRC surgery between January 2019 and April 2022 were selected.
Immune Effect of Co-Culture of Dendritic Cells and Cytokine-Induced Killer Cells on Prostate Cancer Cells.
Cell Biochem Biophys
October 2024
Department of Urology Surgery, Tongxiang First People's Hospital, Tongxiang, 314500, Zhejiang, China.
It was to explore the immune outcome of co-culture of dendritic cells (DC) and cytokine-induced killer cells (CIK) on prostate cancer (PCa) cells. Peripheral blood mononuclear cells (PBMCs) were extracted from healthy blood donors. DC and CIK cells were induced and co-cultured.
View Article and Find Full Text PDFXELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Signal Transduct Target Ther
April 2024
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154) assessed the efficacy and adverse events (AEs) of the combination of PD-1 blockade-activated DC-CIK (PD1-T) cells with XELOX plus bevacizumab as a first-line therapy in patients with mCRC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!